Secondary Logo

Journal Logo

Caring for children with neurofibromatosis type 1

Sampson, Janice, DNP, RN, CNE; Thompson, Heather L., PhD, CCC-SLP; Parilo, Denise M. Wall, PhD, RN

doi: 10.1097/01.NURSE.0000554214.17051.d9
Feature: CE Connection
Free
SDC
CE

Abstract: This article discusses the variable physical manifestations of neurofibromatosis type 1 among children in terms of presentation, disease severity, and prognosis, and addresses appropriate nursing interventions and patient teaching.

In children, the manifestations of neurofibromatosis type 1 vary widely in terms of presentation, disease severity, and prognosis. Here, the authors address appropriate patient assessment, nursing interventions, and education for children and adolescents with this surprisingly common genetic disorder.

Janice Sampson is an associate professor in the School of Nursing, California State University in Sacramento, Calif. Also at California State University in Sacramento, Heather Thompson is an assistant professor in the Department of Communication Sciences and Disorders, and Denise Wall Parilo is a professor in the School of Nursing.

The authors and planners have disclosed no potential conflicts of interest, financial or otherwise.

Figure

Figure

INDIVIDUALIZED CARE for children and families is at the core of improved outcomes in any healthcare arena. The unpredictable course of the genetic neurocutaneous disorder neurofibromatosis type 1 (NF1), which typically manifests during infancy or childhood and progresses throughout life, demands astute nursing assessment skills and comprehensive, ongoing interdisciplinary cooperation.1 Nurses play a key role by using a personalized approach to facilitate the coordination of care. This article discusses the variable physical manifestations of NF1 among children in terms of presentation, disease severity, and prognosis, and addresses appropriate nursing interventions and patient teaching.

Back to Top | Article Outline

About NF1

NF1 is a genetic disorder affecting the epidermal, skeletal, and central nervous systems. It is characterized by multiple benign nerve sheath tumors (neurofibromas) and areas of abnormal skin color (see Key terminology). Neurofibromas usually develop in the skin but can appear anywhere in the body, and they tend to increase in size and number as the patient ages.2

According to the National Organization for Rare Disorders, most children with NF1 have normal intelligence, but about half experience learning disabilities. Many also exhibit attention-deficit hyperactivity disorder (ADHD).2,3

A surprisingly common autosomal dominant genetic disorder, NF1 has an incidence of about 1 in 2,700 births.4 The disorder is caused by a mutation of the NF1 gene on chromosome 17q11.2. This gene regulates production of neurofibromin, a protein expressed in many tissues throughout the body, including the brain, kidney, spleen, and thymus. Neurofibromin is thought to act as a tumor suppressor.5,6 Approximately half of all cases of NF1 are new gene mutations and about half of patients have a family history of the disorder.2,7 NF1 affects both genders and all racial and ethnic groups.8

Signs and symptoms usually appear in infancy or early childhood (see Common signs of NF1).1 A clinical diagnosis of NF1 is made when patients exhibit two or more hallmark characteristics in specific areas, according to guidelines from the National Institutes of Health Consensus Development Conference:9

  • six or more café-au-lait macules (coffee-colored hyperpigmented lesions) of 5 mm or greater in diameter in children and 15 mm or greater in adolescents after puberty
  • two or more neurofibromas or one plexiform neurofibroma (tumors that involve multiple branches of nerves that can occur internally or externally)
  • an optic glioma (tumor of the optic nerve)
  • two or more Lisch nodules, also known as iris hamartomas (small pigmented tumors of the iris)
  • a distinctive bony lesion, such as sphenoid dysplasia or thinning of the long bone cortex with or without pseudoarthrosis
  • freckling in the axillary or inguinal regions
  • a first-degree relative (parent, sibling, or child) with NF1 meeting the above clinical criteria.
Table

Table

While the diagnosis of NF1 is generally based on the clinical criteria, in some unconfirmed cases, genetic testing is completed through the analysis of DNA or mRNA from a blood sample or tissue biopsy.10

Patients suspected of having NF1 should receive a timely evaluation by a knowledgeable team of specialists engaged in interprofessional practice and transdisciplinary care, such as a neurologist, dermatologist, ophthalmologist, orthopedist, psychologist, and speech-language pathologist. Radiographs and other imaging studies should be obtained as needed. An interdisciplinary team or clinic at a major hospital or university treatment center is an excellent resource for initial assessment and follow-up evaluation.

Following the identification of tumors or other physical manifestations, patients should be referred for surgical intervention if indicated for painful or disfiguring tumors, radiation, or chemotherapy following current best practices. For patients seeking support in reproductive health or prenatal counseling, a genetic counselor can help the family make informed decisions.

Back to Top | Article Outline

Disease progression

The range, severity, and rate of progression of NF1 signs and symptoms are unpredictable and can vary with age. Gutmann and colleagues report that infants with NF1 exhibit café-au-lait macules.10 Early in a child's development, orbital or tibial dysplasia may also be observed. Tibial bowing and pseudarthrosis can contribute to mobility impairment, requiring significant medical follow-up and possibly orthopedic intervention for long bone dysplasia or scoliosis.11-13

Preschool children may present with an optic glioma that can impact vision.10 Plexiform, dermal, and paraspinal neurofibromas can emerge in childhood and adolescence. In adolescents with NF1, sexual development may be early (precocious puberty) or delayed.2,10

Tumor progression in NF1 is of considerable concern due to its variability and propensity to affect different body regions, which can contribute to significant pain and decreased quality of life.14 Dermal neurofibromas may cause pruritus but are not usually painful. However, plexiform tumors can be painful if they protrude into proximal structures. The impact of NF1 depends largely on tumor location, the effect on adjacent tissues, and related complications.7

Patients can also experience signs and symptoms beyond those required for a clinical diagnosis of NF1. For example, children with NF1 may present with cardiac anomalies or hypertension.15,16 An elevated risk of cerebral vasculopathy, which can result in a stroke, has also been described as a possible complication in NF1.16,17 Brain malformations, paraspinal neurofibromas, brainstem gliomas, and seizures may occur, requiring careful monitoring and surveillance.10,15 Neurofibromas become malignant in an estimated 8% to 13% of patients.18

Impairments in gross and fine motor functioning have also been reported.19 Delays in motor functioning may impact a child's ability to independently complete activities of daily living such as tying shoelaces or writing.20 Assessments performed early in development can increase the probability that children with NF1 will have access to appropriate services. Early intervention may improve short-term and long-term outcomes.

Back to Top | Article Outline

Treatment options

Due to emerging research, medications for the treatment of patients with clinical manifestations of NF1 are constantly changing and tailored to each patient's unique condition. Many patients take medications to manage ADHD, seizures, and/or pain. Patients with bone dysplasia may be prescribed vitamin D if a deficiency is identified.10

While the current focus of pharmacologic treatment is symptom management (for example, managing ADHD with stimulants), clinical trials are currently underway to evaluate the efficacy of oral selective mitogen-activated protein kinase inhibitors, including the investigational drug selumetinib.21,22 In at least one clinical trial, selumetinib has been shown to shrink large plexiform tumors in children.23 However, further research is needed to evaluate the efficacy of this and other pharmacologic options.

Not only do nurses need to remain up to date on these clinical trials and current research findings, but they also need to be engaged as interdisciplinary team members carrying out research in NF1. Access to current information provided via nurses who are involved directly in research can provide NF1 patients and their families with encouragement and hope for improved outcomes.

Figure

Figure

Back to Top | Article Outline

Addressing developmental issues

Children with NF1 should be assessed for learning disabilities, ADHD, and speech or language impairments.3,24-26 Communication problems can also manifest as deficits in articulation and phonology, impairments in voice (such as a hoarse vocal quality) or resonance (such as hypernasality), or delays in receptive and/or expressive language.25

Behavioral concerns that may impede normal development include deficits in visuospatial ability and social competence.27 Learning difficulties may be compounded by frequent absences from school for medical appointments or hospitalization.

Parents and caregivers of children with NF1 require information to guide lifetime care planning. Synthesizing results of previous investigations, Gutmann and colleagues concluded that individuals with NF1 have a lifespan that is 8 to 21 years shorter than those in the general population.10 For family planning, couples in which one partner has NF1 may consider genetic testing to identify the presence of NF1 in an embryo, but such tests have been shown to be effective only 80% of the time with the possibility of false positives.28

Nurses caring for pediatric NF1 patients should respect parental perspectives and encourage parents to participate in the child's care to help decrease parental anxiety. Family education and emotional support are tools that empower each member of the family to cope more effectively, leading to improved patient outcomes and anticipatory guidance.29

Back to Top | Article Outline

Interdisciplinary teamwork

Nurses play a key role on the NF1 interdisciplinary team from the time of diagnosis through the course of the patient's health journey. Due to the prevalence of NF1 and its disease process, nurses may see these children in almost any setting. For example, nurses may provide services to children identified in the neonatal ICU or during a routine visit for a well-child exam. In these areas, nurses must utilize their assessment skills to help identify children who exhibit symptoms of NF1 such as café-au-lait macules.

In addition, nurses may work with children in specialty clinics (such as medical genetics, neurology, dermatology, gastrointestinal, cardiology, or endocrinology clinics) who are being treated for a specific complication of NF1. In these specialty clinics, the nursing focus is symptom management, prevention of complications, family-centered care, and education. For example, regular BP monitoring will alert the nurse to the potential for hypertension. Collaborating with pharmacists, the nurse can help patients and parents prevent adverse drug reactions and assist with follow-up.

In the home healthcare setting, nurses must establish a plan of care tailored for the child's unique medical needs. In an acute care setting, children may need care for a range of admission diagnoses, from influenza to tumor management, to pre- and postoperative care (see Caring for hospitalized patients).

Besides supporting families at the time of diagnosis, nurses must continue to perform comprehensive assessments to initiate and continue an individualized plan of care as the child develops. Assessments in a clinical setting should include neurologic, orthopedic, dermatologic, renal, and cardiovascular system workups. Nurses should complete assessments with a focus on the presenting diagnosis and stay especially alert for neurologic signs and symptoms, such as cognitive deficits and seizure activity. School nurses may assist children with medications prescribed to manage various disorders or symptoms, such as ADHD, seizures, or pain.

As they grow and develop, children with NF1 need regular ophthalmologic screening and growth assessments. Other indicated screening tests depend on specific signs and symptoms. For example, MRI of the brain is indicated for children who experience seizure activity and for those with accelerated head growth to monitor for hydrocephalus. Those with severe hypertension should be regularly assessed for renal artery stenosis and other complications.

As care for children with NF1 is provided in various settings, nurses are encouraged to seek out opportunities for interdisciplinary education to promote optimal patient care.30

Back to Top | Article Outline

Screening for speech and language deficits

Because children with NF1 are at risk for speech and language impairments, they should also undergo speech, language, and hearing screenings early in their development and receive a referral for a speech-language assessment as soon as possible following identification of speech or language deficits. Currently, research into the effectiveness of speech-language interventions for these children is sparse. However, a computer-based literacy training program demonstrated benefits with school-age patients in at least one recent study.31 These results suggest promise for the utility of interventions in speech, language, and reading.

School nurses should work closely with classroom teachers to provide collaborative care so the child with NF1 can participate in the regular academic curriculum to the greatest extent possible. Recognition of family history and the home environment should always be considered as possible contributing factors of any outliers in a child's academic performance. Other environmental factors can also play a role in how well children with NF1 will progress.

Although many children with NF1 exhibit cognitive functioning that is below the normal range, others perform well academically as a direct result of the support they receive at home and from other resources. Nevertheless, nurses and caregivers should recognize that children may struggle in school as the demands of the educational curriculum increase from the elementary grades to high school. Continuous monitoring and reassessment of school performance is imperative for academic success.

Back to Top | Article Outline

Patient support

To ensure continuity of care, nurses can collaborate with other members of the multidisciplinary team and monitor referrals made to healthcare providers to ensure that patients, families, and caregivers receive what is requested. During routine clinic visits, nurses can administer questionnaires and quality-of-life measures to assess changes over time. Quality-of-life questionnaires have been developed specifically for people with NF1.14,32

A diagnosis of NF1 begins a patient's lifelong journey of interactions with members of the healthcare system. Through numerous medical appointments, patients and families of children with NF1 need to connect with others experiencing this disease process. An excellent and comprehensive resource is the Children's Tumor Foundation, which is a national nonprofit organization with a major emphasis on funding research and improving the care and support of patients with NF1 and their caregivers (see Resources). Regional organizations provide opportunities for patients with NF1 and their families to make connections with healthcare providers and find additional support in their communities.

Back to Top | Article Outline

Caring for hospitalized patients

During hospitalization, patients with NF1 may require care following surgery for tumor removal and/or require attention for comorbidities such as moyamoya, a rare, progressive cerebrovascular disorder caused by arterial occlusion in the basal ganglia.33 Performing a detailed neurologic assessment is a priority to determine baseline functioning.

If a patient with NF1 is hospitalized for a comorbid condition, nurses need to assess for signs and symptoms of complications associated with NF1. For example, headache is a very significant finding that requires follow-up. While many patients experience headaches, a headache in a child with NF1 is urgent because it can indicate an underlying life-threatening condition such as vasculopathy, hypertension, or a space-occupying brain lesion.34 These disorders can cause seizure activity, stroke, or cardiopulmonary arrest.

Nurses also play an essential role in pain management. Children with NF1 may experience pain secondary to their disease process and/or to a surgical or orthopedic procedure. The use of age-appropriate pain intensity assessment tools to determine the level of pain is the first step in pain management.35 The assessed level of pain intensity guides the decision for pain medication. Nonpharmacologic interventions such as distraction (for example, with music, toys, or electronic devices, depending on the child's age) have also been shown to decrease anxiety and pain.36

Back to Top | Article Outline

Resources

Children's Tumor Foundationwww.ctf.org

Genetics Home Reference: Neurofibromatosis type 1https://ghr.nlm.nih.gov/condition/neurofibromatosis-type-1

National Organization for Rare Diseases: Neurofibromatosis 1https://rarediseases.org/rare-diseases/neurofibromatosis-type-1-nf1

Neurofibromatosis Californiawww.nfcalifornia.org

Neurofibromatosis Midwestwww.NFmidwest.org

Back to Top | Article Outline

REFERENCES

1. Korf BR, Bebin EM. Neurocutaneous disorders in children. Pediatr Rev. 2017;38(3):119–128.
2. National Organization for Rare Disorders. Neurofibromatosis 1. https://rarediseases.org/rare-diseases/neurofibromatosis-type-1-nf1.
3. North K, Hyman S, Barton B. Cognitive deficits in neurofibromatosis 1. J Child Neurol. 2002;17(8):605–612.
4. Evans DG, Howard E, Giblin C, et al Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. 2010;152A(2):327–332.
5. Korf BR. Neurofibromatosis type 1 (NF1): pathogenesis, clinical features, and diagnosis. UpToDate. 2018. http://www.uptodate.com.
6. Peltonen S, Kallionpää RA, Peltonen J. Neurofibromatosis type 1 (NF1) gene: beyond café au lait spots and dermal neurofibromas. Exp Dermatol. 2017;26(7):645–648.
7. Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL. Neurofibromatosis type 1 revisited. Pediatrics. 2009;123(1):124–133.
8. National Institutes of Health/National Institute of Neurologic Disorders and Stroke. Neurofibromatosis fact sheet. 2018. http://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Neurofibromatosis-Fact-Sheet.
9. National Institutes of Health Consensus Development Conference. Neurofibromatosis: conference statement. Arch Neurol. 1988;45(5):575–578.
10. Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ. Neurofibromatosis type 1. Nat Rev Dis Primers. 2017;3:17004.
11. Stevenson DA, Hanson H, Stevens A, et al Quantitative ultrasound and tibial dysplasia in neurofibromatosis type 1. J Clin Densitom. 2018;21(2):179–184.
12. Yao Z, Guo D, Li H, et al Surgical treatment of dystrophic scoliosis in neurofibromatosis type 1: outcomes and complications. Clin Spine Surg. 2019;32(1):E50–E55.
13. Korf BR. Neurofibromatosis type 1 (NF1): management and prognosis. 2018. UpToDate. http://www.uptodate.com.
14. Ferner RE, Thomas M, Mercer G, et al. Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality of Life (INF1-QOL) questionnaire. Health Qual Life Outcomes. 2017;15(1):34.
15. Rauen KA. The RASopathies. Annu Rev Genomics Hum Genet. 2013;14:355–369.
16. Terry AR, Jordan JT, Schwamm L, Plotkin SR. Increased risk of cerebrovascular disease among patients with neurofibromatosis type 1: population-based approach. Stroke. 2016;47(1):60–65.
17. Santoro C, Di Rocco F, Kossorotoff M, et al Moyamoya syndrome in children with neurofibromatosis type 1: Italian-French experience. Am J Med Genet A. 2017;173(6):1521–1530.
18. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002;39(5):311–314.
19. Torres Nupan MM, Velez Van Meerbeke A, López Cabra CA, Herrera Gomez PM. Cognitive and behavioral disorders in children with neurofibromatosis type 1. Front Pediatr. 2017;5:227.
20. Casnar CL, Janke KM, van der Fluit F, Brei NG, Klein-Tasman BP. Relations between fine motor skill and parental report of attention in young children with neurofibromatosis type 1. J Clin Exp Neuropsychol. 2014;36(9):930–943.
21. Selumetinib in treating patients with neurofibromatosis type 1 and cutaneous neurofibroma. ClinicalTrials.gov identifier: NCT02839720. https://linicaltrials.gov.
22. National Institutes of Health/National Cancer Institute. Selumetinib continues to show promise in children with NF1. News release. June 8, 2018.
23. Dombi E, Baldwin A, Marcus LJ, et al Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N Engl J Med. 2016;375(26):2550–2560.
24. Orraca-Castillo M, Estevez-Perez N, Reigosa-Crespo V. Neurocognitive profiles of learning disabled children with neurofibromatosis type 1. Front Hum Neurosci. 2014;8(386):1–9.
25. Thompson HL, Stevenson DA, Redmond SM, Smith BM, Viskochil D. Communication disorders associated with neurofibromatosis type 1. In: Karajannis M & Allen J, eds. Neurofibromatosis: Symptoms, Treatment and Prognosis. New York, NY: Nova Science Publishers; 2013:147–168.
26. Isenberg JC, Templer A, Gao F, Titus JB, Gutmann DH. Attention skills in children with neurofibromatosis type 1. J Child Neurol. 2013;28(1):45–49.
27. Lehtonen A, Howie E, Trump D, Huson SM. Behaviour in children with neurofibromatosis type 1: cognition, executive function, attention, emotion, and social competence. Dev Med Child Neurol. 2013;55(2):111–125.
28. Merker VL, Murphy TP, Hughes JB, et al Outcomes of preimplantation genetic diagnosis in neurofibromatosis type 1. Fertil Steril. 2015;103(3):761–768.e1.
29. Tyson ME, Bohl DD, Blickman JG. A randomized controlled trial: child life services in pediatric imaging. Pediatr Radiol. 2014;44(11):1426–1432.
30. Thompson HL, Sampson JL. Interprofessional Education for Improving Care of Patients with Neurofibromatosis Type 1. Poster presentation. 2018 Joint Global Neurofibromatosis Conference, Paris, France. November 2-6, 2018.
31. Arnold SS, Barton B, McArthur G, North KN, Payne JM. Phonics training improves reading in children with neurofibromatosis type 1: a prospective intervention trial. J Pediatr. 2016;177:219–226.e2.
32. Nutakki K, Varni JW, Steinbrenner S, Draucker CB, Swigonski NL. Development of the pediatric quality of life inventory neurofibromatosis type 1 module items for children, adolescents and young adults: qualitative methods. J Neurooncol. 2017;132(1):135–143.
33. National Institutes of Health/National Institute of Neurologic Disorders and Stroke. Moyamoya disease information page. 2018. http://www.ninds.nih.gov/Disorders/All-Disorders/Moyamoya-Disease-Information-Page.
34. Son C, Park JW. Neurofibromatosis type 1 accompanied by craniofacial pain: literature review and descriptive case. J Oral Facial Pain Headache. 2017;31(4):402–409.
35. Wolters PL, Martin S, Merker VL, et al Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials. Neurology. 2016;87(7 suppl 1):S4–S12.
36. Thrane SE, Wanless S, Cohen SM, Danford CA. The assessment and non-pharmacologic treatment of procedural pain from infancy to school age through a developmental lens: a synthesis of evidence with recommendations. J Pediatr Nurs. 2016;31(1):e23–e32.
37. Anastasaki C, Dahiya S, Gutmann DH. KIR2DL5 mutation and loss underlies sporadic dermal neurofibroma pathogenesis and growth. Oncotarget. 2017;8(29):47574–47585.
38. Ji G, Wang K, Jiao C, Lu Z, Li X. Solitary plexiform neurofibroma of the hepatic artery. J Gastrointest Surg. 2018;22(4):757–758.
Keywords:

attention-deficit hyperactivity disorder; café-au-lait macules; genetic disorder; Lisch nodules; neurofibroma; neurofibromatosis type 1; plexiform neurofibroma; selumetinib

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.